Infliximab therapy decreases the expression of serum and faecal miR ‐126 and miR ‐20a in paediatric Crohn's disease: A pilot study
Acta Paediatrica · 2024
DOI: 10.1111/apa.17072 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Paediatrica, 2024. Verfasst von Marianna Casertano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Woman, Child and General and Specialist Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy. Hauptthemen laut MEDLINE: Crohn Disease, MicroRNAs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Aim
We aimed to evaluate the serum and faecal expression of miR‐126 and miR‐20a in children with Crohn's disease (CD) during infliximab (IFX) therapy.
Methods
In this prospective observational study, serum and faeces from CD patients were collected before IFX therapy (T0), after induction (T1) and after 6 months from IFX (T2). IFX levels were determined by Enzyme‐linked immunosorbent assay at T1 and T2. miRNAs were profiled through Real‐Time RT‐PCR. The activity of disease was evaluated through the Paediatric Crohn's disease activity index (PCDAI), serum C‐reactive protein (CRP) and faecal calprotectin.
Results
Nine CD children were enrolled. Serum and faecal miR‐126 and miR‐20a levels were higher at T0 and showed a time‐dependent decrease, being significantly down‐regulated after IFX treatment at T2. Specifically, IFX levels recorded at T1 and T2 negatively correlated with the serum and faecal expression of miR‐126 and miR‐20a. Serum and faecal changes of miR‐126 and miR20‐a were positively associated with the decrease of the inflammatory marker CRP and PDCAI at all time points.
Conclusion
In children with CD, IFX therapy decreases the expression of serum and faecal miR‐126 and miR‐20a, suggesting an involvement of these two miRNAs in the action of the drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Woman, Child and General and Specialist Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Naples, Italy.
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
- PhD Course in Translational Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
- PhD Course of National Interest in Public Administration and Innovation for Disability and Social Inclusion, Department of Mental, Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Napl…
- School of Pharmacology and Clinical Toxicology, University of Campania "Luigi Vanvitelli", Naples, Italy.
ORCID-Profile: Erasmo Miele, Caterina Strisciuglio
Zitieren
APA
Casertano, M., Trotta, M. C., Cenni, S., Creoli, M., Miele, E., Martinelli, M., Lepre, C. C., Russo, M., Alfano, R., D'Amico, M., & Strisciuglio, C. (2024). Infliximab therapy decreases the expression of serum and faecal miR ‐126 and miR ‐20a in paediatric Crohn's disease: A pilot study. Acta Paediatrica. https://doi.org/10.1111/apa.17072
Vancouver
Casertano M, Trotta MC, Cenni S, Creoli M, Miele E, Martinelli M, et al. Infliximab therapy decreases the expression of serum and faecal miR ‐126 and miR ‐20a in paediatric Crohn's disease: A pilot study. Acta Paediatrica. 2024. doi:10.1111/apa.17072
BibTeX
@article{Casertano2024,
author = {Casertano, Marianna and Trotta, Maria Consiglia and Cenni, Sabrina and Creoli, Mara and Miele, Erasmo and Martinelli, Massimo and Lepre, Caterina Claudia and Russo, Marina and Alfano, Roberto and D'Amico, Michele and Strisciuglio, Caterina},
title = {Infliximab therapy decreases the expression of serum and faecal miR ‐126 and miR ‐20a in paediatric Crohn's disease: A pilot study},
journal = {Acta Paediatrica},
year = {2024},
doi = {10.1111/apa.17072}
}
EUVIMED